SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D. C. 20549

                                   FORM 10-QSB

[X]      QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
         ACT OF 1934

                  For the quarterly period ended March 31, 2003

[ ]      TRANSITION REPORT UNDER SECTION 14 OR 15(D) OF THE EXCHANGE ACT

             For the transition period from__________ to ___________

                               BIO-ONE CORPORATION
                               -------------------
                (Name of Registrant as specified in its charter)

           NEVADA                        000-31889               65-0815746
           ------                        ---------               ----------
(State or other jurisdiction of      (Commission File           (IRS Employer
incorporation or organization)            No.)               Identification No.)

     1630 Winter Springs Blvd., Winter Springs, Florida 32708 (407) 977-1005
     -----------------------------------------------------------------------
          (Address and telephone number of principal executive offices)

Check whether the issuer has (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months, (or such
shorter period that the Registrant was required to file such report(s), and (2)
has been subject to such filing requirements for the past 90 days.

                              Yes  (X)         No   (  )

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date: March 31, 2003

           CLASS                                Outstanding at March 31, 2003
           -----                                -----------------------------
  Common Stock $.001 par value                           27,506,781

                        Copies of communications sent to:

                          Newman, Pollock & Klein, LLP
                           2101 NW Corporate Boulevard
                                    Suite 414
                            Boca Raton, Florida 33431

<PAGE>

                               BIO-ONE CORPORATION

PART I:   FINANCIAL INFORMATION                                           PAGE
                                                                          ----

Item 1.   Financial Statement

              Balance Sheet as of March 31, 2003 (Unaudited)
              and December 31, 2002                                         3

              Statement of Operations for the three months
              ended March 31, 2003 (unaudited); and March
              31, 2002                                                      4

              Statement of Cash Flows for the three months
              ended March 31, 2003 (unaudited), and
              March 31, 2002                                                5

              Notes to Consolidated Financial Statements
              (Unaudited) as of March 31, 2003                              6

              Management Discussion and Analysis of Financial
              Condition and Results of Operations                         7-8


PART II.  OTHER INFORMATION                                                 9


                                       2
<PAGE>

                               BIO-ONE CORPORATION

                                 Balance Sheets
<TABLE>
<CAPTION>

                                     Assets
                                     ------

                                                                March 31, 2003  December 31,
                                                                 (Unaudited)       2002
                                                                 -----------    -----------
<S>                                                              <C>                 <C>
Current assets:
     Cash and cash equivalents                                   $   152,250         14,742
                                                                 -----------    -----------

               Total current assets                                  152,250         14,742

     Property and equipment, at cost, net of accumulated
         depreciation and amortization                                 4,752          4,099
     Deposits                                                         53,500             --
                                                                 -----------    -----------

               Total assets                                      $   210,502         18,841
                                                                 ===========    ===========

                      Liabilities and Shareholders' Equity
                      ------------------------------------

Current liabilities:
     Accounts payable                                            $        --        124,596
     Accrued expenses                                                103,375        111,375
     Stockholder loans                                                43,408         71,008
     Current installments of note payable                             74,502         74,502
                                                                 -----------    -----------

               Total current liabilities                             221,285        381,481
                                                                 -----------    -----------

Shareholders' equity:
     Common stock - $.001 par value, authorized 100 million
        shares; issued 27,506,781 shares and 18,854,695 shares        27,506         18,855
     Additional paid in capital                                    2,302,026      1,786,377
     Accumulated deficit                                          (2,340,315)    (2,167,872)
                                                                 -----------    -----------

               Total shareholders' equity                            (10,783)      (362,640)
                                                                 -----------    -----------

                                                                 $   210,502         18,841
                                                                 ===========    ===========
</TABLE>

See accompanying notes to financial statements.


                                       3
<PAGE>

                               BIO-ONE CORPORATION

                            Statements of Operations
<TABLE>
<CAPTION>

                                                          Three Months Ended
                                                                 March 31,
                                                          2003              2002
                                                      (Unaudited)       (Unaudited)
                                                      ------------      ------------
<S>                                                        <C>               <C>
Revenues:
     Net sales                                        $         --            20,720
                                                      ------------      ------------


Costs and expenses:
     Cost of goods sold                                         --             8,909
     Selling, general and administrative                   167,661           163,737
                                                      ------------      ------------

                                                           167,661           172,646
                                                      ------------      ------------

               Operating loss                             (167,661)         (151,926)

Non-operating revenue (expense):
     Interest expense                                       (4,782)           (1,160)
                                                      ------------      ------------

               Loss before income taxes                   (172,443)         (153,086)

Provision for income taxes                                      --                --
                                                      ------------      ------------

               Net loss                               $   (172,443)         (153,086)
                                                      ============      ============

Basic earnings per share                              $      (0.01)            (0.01)
                                                      ============      ============

Diluted earnings per share                            $      (0.01)            (0.01)
                                                      ============      ============

Weighted average number of shares outstanding           21,682,092        12,812,086
                                                      ============      ============
</TABLE>


See accompanying notes to financial statements.


                                       4
<PAGE>


                               BIO-ONE CORPORATION

                            Statements of Cash Flows
<TABLE>
<CAPTION>

                                                                             Three Months Ended
                                                                                  March 31,
                                                                           2003            2002
                                                                        (Unaudited)    (Unaudited)
                                                                         ---------      ---------
<S>                                                                      <C>             <C>
Cash flows from operating activities:
    Net loss                                                             $(172,443)      (153,086)
    Adjustments to reconcile net income to net cash
        provide by operating activities:
           Stock issued for services                                        24,300             --
           Depreciation and amortization                                     5,327          1,000
           Changes in operating assets and liabilities:
               Accounts receivable                                              --         (2,267)
               Inventories                                                      --         (2,516)
               Accounts payable and accrued expenses                      (132,596)       124,247
               Deposits                                                    (53,500)            --
                                                                         ---------      ---------

                    Net cash used in operating activities                 (328,912)       (32,622)
                                                                         ---------      ---------

Cash flows from investing activities:
    Purchase of property and equipment                                      (5,980)            --
                                                                         ---------      ---------

                    Net cash used in investing activities                   (5,980)            --
                                                                         ---------      ---------

Cash flows from financing activities:
    Proceeds from sale of common stock                                     500,000             --
    Proceeds (repayments) of note payable, stockholder                     (27,600)            --
                                                                         ---------      ---------

                    Net cash provided by financing activities              472,400             --
                                                                         ---------      ---------

                    (Decrease) increase in cash and cash equivalents       137,508        (32,622)

Cash and cash equivalents - beginning of period                             14,742         34,103
                                                                         ---------      ---------

Cash and cash equivalents - end of period                                $ 152,250          1,481
                                                                         =========      =========
</TABLE>

See accompanying notes to financial statements.

                                       5
<PAGE>

                               BIO-ONE CORPORATION

                          NOTES TO FINANCIAL STATEMENTS


(1)      PRESENTATION OF UNAUDITED FINANCIAL STATEMENTS
         ----------------------------------------------

         The unaudited financial statements have been prepared in accordance
         with rules of the Securities and Exchange Commission and, therefore, do
         not include all information and footnotes necessary for a fair
         presentation of financial position, results of operations and cash
         flows, in conformity with generally accepted accounting principles. The
         information furnished, in the opinion of management, reflects all
         adjustments (consisting only of normal recurring accruals) necessary to
         present fairly the financial position as of March 31, 2003, and results
         of operations and cash flows for the three month periods ended March
         31, 2003 and 2002. The results of operations are not necessarily
         indicative of results which may be expected for any other interim
         period, or for the year as a whole.

(2)      SALES TO MAJOR CUSTOMERS
         ------------------------

         During the three months ended March 31, 2002, two customers accounted
         for 51%, and 25%, of total revenue.



                                       6
<PAGE>


PART II: OTHER INFORMATION

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

The following discussion and analysis should be read in conjunction with our
financial statements and the accompanying notes appearing subsequently under the
caption "Financial Statements." The following discussion and analysis contains
forward-looking statements, which involve risks and uncertainties in the
forward-looking statements. Our actual results may differ significantly from the
results, expectations and plans discussed.

This Report contains "forward looking statements" relating to our company's
current expectations and beliefs. These include statements concerning
operations, performance, financial condition, anticipated acquisitions and
anticipated growth.

Without limiting the generality of the foregoing, words such as "may", "will",
"would", "expect", "believe", "anticipate", "intend", "could", "estimate", or
"continue", or the negative or other variation thereof or comparable terminology
are intended to identify forward-looking statements. These statements by their
nature involve substantial risks and uncertainties which are beyond our
company's control. Should one or more of these risks or uncertainties
materialize or should our company's underlying assumptions prove incorrect,
actual outcomes and results could differ materially from those indicated in the
forward-looking statements.

Bio-One Corporation was formed for the purpose of serving the emerging niche of
preventive and alternative healthcare. This niche has grown to a multi-
billion-dollar nutritional supplement based marketplace. The market is
considered to be global.

We intend to pursue a strategy of consolidation becoming one of the first
companies to consolidate through vertical integration mergers and
marketing/distribution acquisitions. Our principle goal will be to acquire and
operate multiple manufacturing and marketing businesses in the nutritional
supplements industry with sales under $25 million. Management believes that the
nutritional supplement market is ripe for consolidation. When market valuations
support it, consolidation by aggregation is the most profitable approach. We
believe that these conditions apply today in the consumer health care industry,
specifically within the nutritional supplements segment. Our business plan is to
consolidate at least one high-level manufacturing business and several
distributors/marketers that fit the strict criteria we established. We have
engaged the services of certain parties to represent us with the Wall Street
investment banking community and institutional investors. We have also engaged
Health Business Partners, one of the nutrition industry's leading mergers and
acquisition consultants to identify the prospective the acquisitions. We are in
the process of assembling the management team with the requisite experience to
lead this growth, and in furtherance thereof have taken the following actions:

                                       7
<PAGE>


         1. In January Cornell Capital Partners, L.P. invested $500,000 under
the terms of our Equity Line Agreement. The shares are to be valued and issued
in 12 puts over a period of 125 days. We issued 5 million shares of our common
stock in connection with this financing.

         2. On January 10 we signed a term sheet with Investors Corporation,
which provides in part for $10 million in acquisition financing and a $5 million
revolving line of credit. Each loan calls for payment of interest at the rate of
prime plus 3% and 3.5% respectively. Funding will be subject to completion by
Investors Corporation of their due diligence. As a result, there can be no
assurance that we will receive this financing or in the alternative, that if
this financing is obtained that we will be able to profitably implement our
business strategy.

REVENUES AND EXPENSES FOR THE THREE MONTHS ENDED MARCH 31, 2003 AS COMPARED TO
THE THREE MONTHS ENDED MARCH 31, 2002

We had no revenues during this past quarter as compared to $20,720 for the three
months ended March 31, 2002. Our operating loss increased from $153,086 to
$172,443. Our lack of revenues is due to management's decision to either
terminate or dispose of unprofitable operations and concentrate on potential
acquisition candidates. The increase in our operating loss is attributable to
due diligence fees incurred relating to the pending closing with Investors
Corporation on $15 million in acquisition financing.

LIQUIDITY AND CAPITAL RESOURCES

Our current assets increased from $14,742 as of December 31, 2002 to $152,250 as
of March 31, 2003. Our total assets increased from $18,841 to $210,502. This
increase is attributable to the $500,000 equity investment. Total liabilities
decreased from $381,481 to $221,285.

Management remains focused on implementing the Bio-One business plan. The
Company plans to expand by acquiring other companies and using a combination of
cash, notes and our common stock to finance the future acquisitions. For
additional information, please see the section on "Subsequent Events."

SUBSEQUENT EVENTS

During April, Bio-One signed an agreement with Famco Acquisition Company, LLC,
which provides in part for a $30 million equity investment. Under the terms of
the agreement Famco would receive convertible preferred stock valued at $1.00
per share and bearing a 10% coupon. We have been advised that institutional
financing commitments made to Famco have been breached. As a result, we do not
believe that Famco will be a viable funding source. However, Famco has until
June 30 to perform, otherwise the agreement expires. As a result there can be no
assurance that we will receive this financing or in the alternative, that if
this financing is obtained that we will be able to profitably implement our
business strategy.

Currently the Company is in negotiations with two acquisition candidates that
reported 2002 sales totaling $40 million and EBITDA of $4.3 million. Subject to
Bio-One securing sufficient financing, the parties anticipate closing of the
transactions within the next 60 days.


                                       8
<PAGE>


PART II. OTHER INFORMATION

Item 1. Legal Proceedings
-------------------------

NONE

Item 2. Change in Securities
----------------------------

Following is a list of our securities that we have issued during the last
quarter.

     Name                   Date Acquired   Number of Shares     Consideration

Cornell Capital Partners         01/03         8,250,821          $500,000
Irwin Newman                     01/03            73,045          Consulting (1)
Jeffrey Gerstein                 01/03             8,115          Consulting (1)
Frank Clark                      02/03           179,105          Consulting (1)
Scott Sieck                      02/03           141,000          Consulting (1)


1. We relied upon Section 4(2) of the Securities Act of 1933, as amended (the
"Act") and Rule 506 of Regulation D promulgated thereunder for the issuance of
our common stock.

Item 3. Defaults Upon Senior Securities
---------------------------------------

We have not issued any senior securities and as such there have been no
defaults.

Item 4. Submission of Matters to a Vote of Security Holders
-----------------------------------------------------------

We have not submitted any matters to a vote of our security holders, whether
through proxy or otherwise, during the quarter ended March 31, 2003.

Item 5. Other Information
-------------------------

None.

Item 6. Exhibit
---------------

99.1 Financial Certification


                                       9
<PAGE>


                                   SIGNATURES

Pursuant to the requirements of the Exchange Act, this report has been signed by
the following persons in the capacities and on the dates indicated.

Signature                           Title                          Date
---------------                 ---------------               --------------


/s/ Armand Dauplaise
-------------------------
    Armand Dauplaise            President/Chairman/              May 14, 2003
                                CEO/Treas/Asst Sec


/s/ Irwin Newman
------------------------
    Irwin Newman                Secretary                        May 14, 2003




                                       10
<PAGE>

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, Armand Dauplaise, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of Bio-One Corporation;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. I am responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
registrant and we have:

a) Designed such disclosure controls and procedures to ensure that material
information relating to the registrant, particularly during the period in which
this quarterly report is being prepared;

b) Evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and

c) Presented in this quarterly report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. I have disclosed, based on r my most recent evaluation, to the registrant's
auditors and the audit committee of registrant's board of directors (or persons
performing the equivalent function):

a) All significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. I have indicated in this quarterly report whether or not there were
significant changes in internal controls or in other factors that could
significantly affect internal controls subsequent to the date of our most recent
evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.



     Date:   May 14, 2003                   / S /  Armand Dauplaise
                                            -------------------------
                                            Armand Dauplaise
                                            Chief Executive Officer ,
                                            President and Director


                                       11